Clinical trials: Withdrawal
Pain, Low Back Pain
Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain
The purpose of this study is to determine whether buprenorphine hydrochloride (HCl) buccal film is effective and safe in the treatment of chronic low back pain (CLBP).
- Trial name
- NCT01256450
- Testing
- Buprenorphine
- Where
- 24 sites in United States
- Volunteers
- 334 people
- Sponsor
- BioDelivery Sciences International
Nasolabial Folds
An Efficacy and Safety Study of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds
Investigational Device : TheraFill® (Atelocollagen Dermal Filler) Title : A Randomized, Multicenter, Prospective and Paired Comparison of the Efficacy and Safety of TheraFill® versus KOKEN for 3months on Nasolabial Folds Sites…
- Trial name
- NCT01060943
- Testing
- KOKEN, Atelocollagen Filler
- Where
- South Korea
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Cellontech Co., Ltd.
Rheumatoid Arthritis
Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)
The purpose of this study is to investigate the safety and efficacy of Cimzia given as an add-on to your current therapy with disease-modifying anti-rheumatic drug(s) (DMARDs)including MTX or given as monotherapy (alone) over an…
- Trial name
- NCT01489384
- Where
- 13 sites in Canada
- Volunteers
- 125 people
- Sponsor
- Pope Research Corporation
Diabetic Peripheral Neuropathy
Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy
A study to demonstrate the effectiveness of PEMF treatment compared to sham treatment in changing Vibration Perception Threshold (VPT) and Thermal Sensory (QST) in patients with diabetic peripheral neuropathy (DPN) when treatment…
- Trial name
- NCT03077893
- Testing
- Active Provant Therapy System
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Regenesis Biomedical, Inc.
Systemic Juvenile Idiopathic Arthritis With Active Flare
Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
This two-part study assessed the sustained efficacy of canakinumab in the double-blind Part II and the ability to taper steroids in the open label Part I.
- Trial name
- β-SPECIFIC 2 (NCT00889863)
- Testing
- canakinumab
- Where
- 73 sites in United States, Argentina and 17 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Friedreich's Ataxia
Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)
This is a Phase IIIb Double-Blind, Randomised, Placebo-Controlled Study. The aim is to further investigate the effects of idebenone in patients with Friedreich's ataxia.
- Trial name
- PROTI (NCT01303406)
- Testing
- Idebenone
- Where
- 6 sites in Austria, Germany and 2 more
- Volunteers
- 29 people
- Sponsor
- Santhera Pharmaceuticals
Binge Eating Disorder
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
To evaluate maintenance of efficacy based on time to relapse between SPD489 (50 or 70mg) and placebo, as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by…
- Trial name
- NCT02009163
- Testing
- Lisdexamfetamine dimesylate
- Where
- 53 sites in United States, Canada and 3 more
- Volunteers
- 418 people
- Sponsor
- Shire
Schizophrenia and Predominant Negative Symptoms
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as…
- Trial name
- NCT00922272
- Testing
- SPD489 (lisdexamfetamine dimesylate)
- Where
- 27 sites in United States
- Volunteers
- 92 people
- Sponsor
- Shire
Opioid Withdrawal, Pain
BRIDGE Device for Treatment of Opioid Withdrawal
The purpose of this study is to prospectively evaluate the effectiveness of the NSS-2 BRIDGE device in reducing the signs and symptoms of acute opioid withdrawal when compared to placebo.
- Conditions
- Opioid Withdrawal, Pain, Craving
- Trial name
- NCT04162145
- Testing
- Active BRIDGE device placement, Inactive BRIDGE device placement
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BrightView LLC
Kidney Transplantation
Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation
The primary objective of this study is to investigate the impact of early corticosteroid withdrawal in paediatric renal transplant patients on growth expressed as change in height standard deviation score (SDS) from baseline to…
- Trial name
- TWIST (NCT00296348)
- Testing
- tacrolimus, mycophenolate mofetil, daclizumab
- Where
- 35 sites in Belgium, Czechia and 12 more
- Volunteers
- 198 people
- Sponsor
- Astellas Pharma Inc
Painful Diabetic Neuropathy
Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.
SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful…
- Trial name
- NCT00546351
- Testing
- Lacosamide
- Where
- 101 sites in Austria, Belgium and 13 more
- Volunteers
- 621 people
- Sponsor
- UCB Pharma
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
- Trial name
- EXPAND (NCT04666610)
- Testing
- Brivaracetam
- Where
- 35 sites in United States, Georgia and 5 more
- Volunteers
- 154 people
- Sponsor
- UCB Biopharma SRL
Juvenile Rheumatoid Arthritis
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept).
- Trial name
- NCT00095173
- Testing
- Abatacept
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 214 people
- Sponsor
- Bristol-Myers Squibb
Dermatitis Atopic
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ESTUARY (NCT06407934)
- Testing
- Amlitelimab
- Where
- 324 sites in United States, Argentina and 25 more
- Volunteers
- 1,541 people
- Sponsor
- Sanofi
Schizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
- Trial name
- NCT07227818
- Testing
- NBI-1117568
- Where
- 25 sites in United States, Puerto Rico and 1 more
- Volunteers
- 560 people
- Sponsor
- Neurocrine Biosciences
Autism Spectrum Disorders
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in subjects with autism spectrum disorders
- Trial name
- NCT01288716
- Testing
- Arbaclofen
- Where
- 24 sites in United States
- Volunteers
- 150 people
- Sponsor
- Seaside Therapeutics, Inc.
Treatment for Opioid Use Disorder
A Study to Train a Machine Learning Algorithm for an Evaluation of the Use of Biometric Data Captured at the Wrist for the Identification of Acute Opioid Use Events and the Quantification of Opioid Withdrawal in Opioid Dependent Individuals
To train a machine learning model/algorithm for an evaluation of the use of biometric data captured at the wrist for the identification of acute opioid use events and the quantification of opioid withdrawal in opioid dependent…
- Trial name
- NCT07405398
- Testing
- Train and evaluate the accuracy and reliability of the Strength Band Platform in identifying acute opioid dosing events from time-stamped biometric data collected from wrist-worn devices.
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- OpiAID
Psoriasis
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.
- Trial name
- OASIS-1 (NCT03482011)
- Testing
- Mirikizumab
- Where
- 69 sites in United States, Germany and 7 more
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
Opioid Dependence, Methadone Withdrawal Syndrome
Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients
The primary objective of this study is to assess QTc (an interval of the heart rhythm) interaction effects between lofexidine and methadone.
- Trial name
- NCT01650649
- Testing
- Lofexidine HCl, Lofexidine-matching sugar pill
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Narcolepsy With Cataplexy
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
This is a double-blind, placebo-controlled, randomized-withdrawal, multicenter study of the efficacy and safety of JZP-258.
- Trial name
- NCT03030599
- Testing
- JZP-258
- Where
- 25 sites in United States, Belgium and 4 more
- Volunteers
- 201 people
- Sponsor
- Jazz Pharmaceuticals